



For more information, contact:

Susan Wirth
Account Supervisor – Public Relations
LePoidevin Marketing
(262) 754-9550
susan@lepoidevinmarketing.com

FOR IMMEDIATE RELEASE

Bionote USA Unveils New and Improved Quantitative In-Clinic SDMA 2.0

Innovative technology enhances usability, improves efficiency

BIG LAKE, MINN. (August 25, 2025) – Veterinary diagnostics company Bionote USA introduces an updated version of its quantitative in-clinic Symmetric Dimethylarginine (SDMA) test for canine and feline patients – SDMA 2.0. The enhancements to the test align with feedback from veterinarians to increase its ease-of-use in the clinic and the speed with which results are available.

The testing procedure has been streamlined, now requiring only three steps to deliver precise quantitative measurements at the point of care to save time for busy veterinary professionals. SDMA 2.0 also requires a smaller sample size of just 25 µl serum or plasma and produces results faster, now in just 10 minutes.

“Veterinarians across the industry have shown high demand for the SDMA test since we added it to our test portfolio in 2023, and they have been happy to provide their insight for how we can make it an even better diagnostic resource,” said Bionote USA President Randy Knick. “At Bionote, our mission is to reduce barriers to care and give veterinarians the power to practice medicine the way they have always wanted. The feedback we receive from the industry coupled with our team of expert researchers and developers help us to optimize our offerings and best serve veterinarians.”

In clinical practice, SDMA is a biomarker used for the analysis of renal function. Applications of quantitative SDMA testing include diagnosis of acute kidney injury and chronic kidney disease, staging of chronic kidney disease, monitoring patients with renal disease and regular check-up testing for early screening.

In addition to SDMA, The Vcheck V200 offers quantitative in-clinic results for 16 other critical biomarker tests across canine, feline and equine care. This diagnostic line has become a popular choice for

veterinarians to incorporate into their practice due to its real-number values at the point of care, affordability, fast results available in minutes, proven accuracy and industry-exclusive tests such as Canine and Feline Troponin I (TnI), Feline NT-proBNP and Canine Cortisol.

For more information on SDMA 2.0, visit www.bionote.com/vcheck-sdma. To learn more about Bionote's other quantitative in-clinic analyzers and tests, visit www.bionote.com/veterinary-products.

#

ABOUT BIONOTE USA

A leading research and development company, Bionote USA helps both veterinarians and medical professionals worldwide by researching and creating solutions in the diagnostic space. Combining in-clinic and microbiology experiences, Bionote USA was formed to bring diagnostic tools that fulfill best-in-care practice needs to the North American veterinary marketplace. This forward-focused, problem-solving approach to patient care resulted in the development of Vcheck and its premium line of in-clinic, quantitative diagnostic tests which provide an actual numerical result - not positives, negatives or estimates. With thousands of Vcheck analyzers placed in veterinary clinics worldwide, Bionote allows veterinarians treating canine, feline and equine patients to prescribe better care at the point of care. For more information, please visit www.bionote.com.